Fate Therapeutics (FATE), announced that Scott Wolchko, the company’s President and CEO, will retire effective December 31, 2024. Fate’s current President of Research and Development, Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO as of January 1, 2025. Fate Therapeutics will passionately continue its mission to develop novel off-the-shelf cellular immunotherapies to broadly treat patients in need. “I would like to thank Scott for his leadership and contributions since the Company’s founding and his vision in establishing Fate as a leader in creating multiplexed-engineered living drugs to tackle complex diseases and delivering them as safe and cost-effective medicines that are available on-demand,” said Bill Rastetter, Fate’s Chairman of the Board of Directors. “I have learned from Scott and admired his unique insights on building strategic differentiation into our product platform and product candidates.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Biotech Alert: Searches spiking for these stocks today
- Fate upgraded to Neutral at BofA after FT819 achieves DORIS remission
- Fate Therapeutics upgraded to Neutral from Underperform at BofA
- Stifel ‘impressed’ with results for Fate Therapeutics’ first FT819 LN patient
- Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial